Rifaximin

Generic Name: Rifaximin

Brand Names: Xifaxan, Zaxine

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₁N_₃O_₁₁

CAS Number: 80621-81-4

Unique Ingredient Identifier: L36O5T016N

Background: Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...

Indication: Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...

Associated Conditions: Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea

Associated Therapies: -

Clinical Trials

Hepatic Encephalopathy Clinical Trials 2024: EMA, PDMA, FDA

DelveInsight's 'Hepatic Encephalopathy Pipeline Insight, 2024' report details the clinical development scenario and growth prospects for Hepatic Encephalopathy treatments, covering 3+ key companies and 3+ therapies in various stages of development, including Xifaxan, Golexanolone, and VE-303. The report provides insights into mechanism of action, route of administration, and market dynamics.

insights.citeline.com

a month ago

Skinny Label Limits: Supreme Court Denies Norwich Bid For US Xifaxan Reprieve

The US Supreme Court denied Norwich Pharmaceuticals' petition to review a case blocking its generic Xifaxan approval until 2029, despite removing the patent-protected indication from the label.

devdiscourse.com

a month ago

Latest Health Developments: From Breakthrough Pills to Legal Battles

U.S. Supreme Court declines Xifaxan patent appeal; Wyoming judge rules anti-abortion laws unconstitutional; Medtronic boosts profit expectations; Ōura's valuation exceeds $5 billion; Eli Lilly's cholesterol drug shows promise; Merck introduces injectable Keytruda.

investingnews.com

2 months ago

ACG Presidential Plenary to Highlight Analysis of Xifaxan Risk Reduction of Overt Hepatic ...

Thermo Fisher Scientific reports Q3 revenue of $10.60 billion, GAAP EPS of $4.25, and adjusted EPS of $5.28. The company launched innovative products like the Thermo Scientific Iliad scanning transmission electron microscope and the Applied Biosystems MagMAX Sequential DNA/RNA kit. Thermo Fisher also deepened partnerships, including with the National Cancer Institute, and expanded its Cincinnati and Bend sites. CEO Marc N. Casper highlights strong financial results and the company's growth strategy, positioning for 2024 objectives.

stocktitan.net